Nicotine Gum Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (2mg, 4mg, 6mg), By Distribution Channel (Supermarkets and Hypermarkets, Pharmaceuticals, Online Channels), And By Geography - Forecasts From 2023 To 2028

The nicotine gum market is anticipated to expand at a high CAGR over the forecast period.

Nicotine gum is a smoking cessation aid accessible over the counter (OTC). It aims to support those who are habituated to tobacco to decrease their cigarette consumption and eventually break the habit of smoking.

Nicotine Gum Market Trends:

Chewing the gum releases nicotine, which is then taken up by the mouth's lining and absorbed into circulation. This aids in progressively lessening nicotine cravings, withdrawal symptoms, and the yearning to smoke. It is frequently obtainable in three different strengths, 2 mg, 4 mg, and 6 mg, contingent on the quantity of nicotine it contains. Individuals’ usage renders to how many cigarettes they smoke each day. One of the foremost factors fueling the market's expansion is the upsurge in cases of lung cancer and other respiratory diseases. Smoking is recognized to be a contributory influence to a number of chronic conditions, including coronary heart disease (CHD), oropharyngeal cancer, esophageal cancer, stroke, rheumatoid arthritis, TB, and several immune-related illnesses.

Rising health consciousness and increased knowledge of these illnesses are mutually driving the market's expansion. An additional feature that endorses expansion is the increasing use of smoking cessation treatments. Abundant administrations and non-governmental organizations (NGOs) in established and emerging countries are promoting the usage of smoking cessation aids like nicotine gums to support people, specifically young people, who are addicted to tobacco. Supplementary aspects are anticipated to fuel the industry, such as numerous product expansions like the formation of rising urbanization, nicotine lozenges, and substantial research and development efforts.

Nicotine Gum Market Growth Drivers:

• Promotions for the anti-smoking movement to aid market development

People who want to break the habit of smoking can take nicotine gum every two hours to gratify their cravings. It is predicted that increased R&D will upsurge product demand, as will government and non-government organizations' advertising of the product. Furthermore, manufacturers encourage anti-smoking efforts and introduce cutting-edge products like lozenges and gum to ward off the necessity to smoke. Furthermore, it is estimated that increased rates of smoking-related illnesses, including lung cancer, boost product demand. These fundamentals spur the market for nicotine gum to expand.

However, market expansion in the subsequent years is estimated to be constrained by nicotine gum's adverse effects.

• An increasing number of people trying to quit smoking can be a major growth factor

People who desire to stop smoking are experimenting with a diversity of smoking cessation aids, including e-cigarettes. Abundant universal public responsiveness initiatives and campaigns aim to persuade the public to give up smoking. For instance, on May 31 every year, "World No Tobacco Day" is observed by the World Health Organization (WHO). Such initiatives increase public consciousness of the undesirable effects of smoking on one's health and encourage the acceptance of sensible measures to curtail tobacco use. The "Campaign for Tobacco-Free Kids" encourages individuals to quit smoking and lessen tobacco's terrible toll on a global scale. Throughout the forecast period, a number of these awareness campaigns are anticipated to fuel market expansion.

Nicotine Gum Market Geographical Outlook:

• North America is projected to be the prominent market shareholder in the nicotine gum market and is anticipated to continue throughout the forecast period.

Because of government programs and campaigns, there has been an immense growth in the proportion of health-conscious customers in North America, which has in turn supported the industry's expansion here. Major brands are also present in the area, and they are concentrating on developing new products to meet the market's mounting demand for nicotine gums. For instance, Nicorette lately presented a smoother-textured nicotine gum product enclosed ice mint lozenge. These essentials are predicted to fuel market expansion over the forecast period. The major part of the market for nicotine gum here is measured by the United States.

Due to increasing sales of nicotine products in nations like Germany, the United Kingdom, France, Italy, etc. Europe also holds a generous portion of the market. Furthermore, the provincial administration is emphasizing the employment of smoking cessation methods profoundly.

However, Asia Pacific is projected to experience robust CAGR growth over the analysis period owing to the increasing customer demand for additional developed products, amplified rivalry amongst tobacco companies, and growing commercial opportunities. Japan is anticipated to remain the area with the strongest progress over the forecasting period. It is estimated that the firm anti-smoking laws passed in China and India will lift demand for substitute items like nicotine gums.

Nicotine Gum Market Key Developments:

• In February 2022, the first generic nicotine chewing gum, sold under the trade name Nicotine beta, was introduced to the German market by Enorama Pharma's business partner, Beta Pharm Arzneimittel GmbH. Nicotine Beta will promote the benefits of NRT with a generic medication (Nicotine Replacement Therapy).
• In July 2021, Fertin Pharma, a producer and developer of health and pharmaceutical products using intra-oral and oral delivery technologies, was purchased by Philip Morris International.

Nicotine Gum Market Scope:

Report Metric	Details
Growth Rate	CAGR during the forecast period
Base Year	2021
Forecast Period	2023–2028
Forecast Unit (Value)	USD Billion
Segments Covered	Type, Distribution Channel, And Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	GlaxoSmithKline Plc, Johnson and Johnson, Novartis Consumer Health, ITC Limited, Cipla Health Limited, Perrigo Company Plc, Fertin Pharma, Alchem International, Revolymer
Customization Scope	Free report customization with purchase

 

Nicotine Gum Market Segmentation:

• By Type
  • 2mg
  • 4mg
  • 6mg
• By Distribution Channel
  • Supermarkets and Hypermarkets
  • Pharmaceuticals
  • Online Channels
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

 

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. NICOTINE GUM MARKET ANALYSIS, BY TYPE 

5.1. Introduction

5.2. 2mg

5.3. 4mg

5.4. 6mg

 

6. NICOTINE GUM MARKET ANALYSIS, BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Supermarkets and Hypermarkets

6.3. Pharmaceuticals

6.4. Online channels

 

7. NICOTINE GUM MARKET ANALYSIS, BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Others

7.5. The Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Indonesia

7.6.6. Thailand

7.6.7. Others

 

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

 

9. COMPANY PROFILES

9.1. GlaxoSmithKline Plc

9.2. Johnson and Johnson

9.3. Novartis Consumer Health

9.4. ITC Limited

9.5. Cipla Health Limited

9.6. Perrigo Company Plc

9.7. Fertin Pharma

9.8. Alchem International

9.9. Revolymer

GlaxoSmithKline Plc

Johnson and Johnson

Novartis Consumer Health

ITC Limited

Cipla Health Limited

Perrigo Company Plc

Fertin Pharma

Alchem International

Revolymer